Therefore, in order to further verify the effect of MEK1/2/Nrf-2 signaling pathway and LMP1 on lymphoma cell resistance and autophagy, we added MEK1/2-specific inhibitor SL327 to the KHYG-1 cells overexpressing LMP1 and added Nrf-2-specific activator cheirolin to the SNK-6 cells poorly expressing LMP1 with DMSO as the control for both. The gene discussed is MAP2K1; the disease is lymphoma.